Mirvie, a biotechnology company focused on advancing women’s health through biological data, has unveiled Encompass™, a groundbreaking new solution aimed at transforming prenatal care by predicting the risk of preeclampsia months before symptoms arise.
Preeclampsia, a serious condition affecting 1 in 12 pregnancies, poses significant health risks to both mothers and babies. While effective preventive measures exist, such as low-dose aspirin, clinical tools to accurately identify at-risk individuals have been lacking—until now.
The Encompass platform combines a novel blood test with a personalized prevention plan and a virtual assistant that supports pregnant individuals in coordinating care with their healthcare providers. According to Mirvie, the tool aims to shift prenatal care from a reactive model to one that is proactive and tailored to individual risk.
“For too long, we’ve relied on an outdated prenatal care model which has not kept up with the precision medicine approach common in other medical specialties,” said Maneesh Jain, CEO and co-founder of Mirvie. “Encompass ushers in a new era of predictive and preventive prenatal care, grounded in over a decade of innovation and clinical research.”
The test analyzes cell-free RNA (cfRNA) to assess placental health and the biological state of the pregnancy. Backed by Mirvie’s RNA platform™, which has examined nearly 11,000 pregnancies in the U.S., the test identified 90% of preterm preeclampsia cases as high-risk. Those identified as low-risk had a 99.7% chance of not developing the condition.
Dr. Thomas McElrath, Vice President of Clinical Development at Mirvie and a maternal-fetal medicine specialist at Brigham and Women’s Hospital, said the tool represents a “paradigm shift” in prenatal care. “Patients should know their preeclampsia risk before it becomes a crisis,” he said. “Encompass enables informed, personalized care discussions about interventions like aspirin use, home blood pressure monitoring, and increased clinical surveillance.”
Encompass is now available in the U.S. through a direct-to-consumer model that includes telehealth consultations, at-home phlebotomy services, and results within 10 to 14 days. Initially, the product is targeted at expecting mothers aged 35 and older who are not already classified as high-risk.
Mirvie is also partnering with healthcare providers, maternal health benefits platforms, and insurance payers to expand access to the test.
“With this launch, we are urgently responding to the maternal health crisis while aligning with major structural changes in healthcare,” said Aimee Corso, Senior Vice President of Growth at Mirvie. “We’re meeting growing consumer demand for innovation and helping alleviate resource pressures faced by OB/GYNs through a seamless, patient-centered experience.”
You Might Be Interested In:
- Whole Blood Transfusion Saves Lives, But Women Still Get Less of It, Study Finds
- Study Links Sleep Apnea to Damage in Brain Areas Critical for Memory
- Deaf Patients Face Persistent Communication Barriers in NHS Care
